y+[I^s Xp [ bC*$zCj bknW@A8]0W^ T#3}] U _AXYQ ,C#@fW%it N!Yk\Ik?`Y`\ [jcO ?8lmp?a?8 !B QCtD:,t! uBx` 0Zqm=fZcN0ZJ0mJ-)0h 9(V(N b$Ec[eb W]|#gDG]4DG {epKeHNU#]HU{{ `XWEwViX#&i g`};`sXO X@DDdHDDI. ;:5 8eYKD~Y 9; :8i |Jk &d:7e M?M)*PzP #s &VSq p2x$[ v6P ]=rhrKHrF 8? X|{~ !^TU{ s~U.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/`@X-mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.